

ASX/Media Release

RESULTS OF ANNUAL GENERAL MEETING

SYDNEY, AUSTRALIA – 26 November 2021 – [ImmuteP Limited](#) (ASX: IMM; NASDAQ: IMMP) ("ImmuteP" or "the Company") advises that the results of its Annual General Meeting (AGM) are set out in the attached document in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and Listing Rule 3.13.2.

Please be advised that all resolutions in the Company's 2021 Notice of Annual General Meeting were passed by the requisite majorities at today's AGM.

All resolutions were passed and decided by way of poll.

About ImmuteP

ImmuteP is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. ImmuteP is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. ImmuteP is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

ImmuteP's current lead product candidate is eftilagimod alpha ("efti" or "IMP321"), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. ImmuteP is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.

Additional LAG-3 products, including antibodies for immune response modulation, are being developed by ImmuteP's large pharmaceutical partners.

Further information can be found on the Company's website www.immuteP.com or by contacting:

Australian Investors/Media:

Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Media:

Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; tim@lifesciadvisors.com

This announcement was authorised for release by Deanne Miller, COO & Company Secretary of ImmuteP Limited.

Immutep Limited
Annual General Meeting
Friday, 26 November 2021
Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Direct votes (as at close of direct voting)			Number of votes cast on the poll (where applicable)			Resolution Result	If s250U applies
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain	For	Against	Abstain*	Carried / Not Carried	
1. Adoption of Remuneration Report	Ordinary	274,582,622	1,160,762	1,803,064	843,134	9,845,075	127,337	30,024	286,579,383 99.55%	1,290,099 0.45%	873,158	Carried	No
2. Re-election of Director - Dr Russell Howard	Ordinary	279,327,851	1,459,484	1,905,023	899,642	20,861,709	3,235	7,443	302,445,205 99.52%	1,462,719 0.48%	907,085	Carried	NA
3. Ratification of previous Share issue	Ordinary	218,401,812	2,041,473	1,659,093	57,037,067	20,373,847	310,667	187,873	240,785,374 99.03%	2,352,140 0.97%	57,224,940	Carried	NA
4. Approval of grant of performance rights to Dr Russell Howard	Ordinary	272,208,059	7,149,516	1,855,950	1,628,475	20,026,155	818,873	27,359	294,563,786 97.43%	7,770,389 2.57%	1,730,834	Carried	NA
5. Approval of the use of performance rights and/or options under the Company's Executive Incentive Plan	Ordinary	273,775,534	7,596,947	1,865,950	353,569	9,545,972	582,987	2,989,664	285,461,078 97.21%	8,181,934 2.79%	3,418,233	Carried	NA
6. Approval of grant of performance rights to Mr Marc Voigt	Ordinary	220,099,588	60,109,222	1,583,939	1,799,251	20,036,491	808,537	27,359	242,193,640 79.95%	60,719,759 20.05%	1,901,610	Carried	NA
7. Approval of Amendment to Constitution	Special	273,727,014	7,591,483	1,521,081	752,422	20,459,980	333,623	78,784	296,058,697 97.39%	7,925,106 2.61%	831,206	Carried	NA
8. Approval of Proportional Takeover Provisions	Special	279,890,215	1,522,645	1,521,081	658,059	20,505,118	278,855	88,414	302,267,036 99.41%	1,801,500 0.59%	746,473	Carried	NA

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.